Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 10
In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.